Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Benefit-Cost Analysis | Health Systems | Maternal/Reproductive Health | Infectious Diseases | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2016DCP3: Reproductive, Maternal, Newborn, and Child Health
This report from the World Bank is the second volume of the Disease Control Priorities, …
This report from the World Bank is the second volume of the Disease Control Priorities, Third Edition (DCP3) series. It focuses primarily on maternal conditions, childhood illnesses, and malnutrition, addressing topics from maternal mortality and morbidity, to acute illness and undernutrition in children under five, to the transition to older childhood and the illnesses that accompany this transition. The Disease Control Priorities Network (DCP) promotes and supports the use of economic evaluation for priority setting…
Evidence Synthesis | Health Systems | Maternal/Reproductive Health | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Global Governance | Economics/Finance | Health/Medicine | Global -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Evidence Synthesis | Benefit-Cost Analysis | Environmental Health | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Injuries/Accidents | Policy/Regulation | Global Governance | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine | Global -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Evidence Synthesis | Health Systems | Infectious Diseases | Technology Assessment | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology | North America -
ReportPublication 2017DCP3: Major Infectious Diseases
This report from the World Bank is the sixth volume of the Disease Control Priorities, …
This report from the World Bank is the sixth volume of the Disease Control Priorities, third edition (DCP3) series and examines the burden of infectious diseases, which remain a leading cause of death globally, especially for children and adolescents. This report identifies feasible and cost-effective platforms to prevent and treat diseases like HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and tropical diseases. This volume also emphasizes the importance of addressing…
Evidence Synthesis | Health Systems | Infectious Diseases | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Global Governance | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2014Valuing Vaccination
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps …
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with…
Benefit-Cost Analysis | Health Systems | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Health Systems | Environmental Health | Priority Setting/Ethics | Mathematical Models | Technology Assessment | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Infectious Diseases | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | Infectious Diseases | Preferences/Values | Policy/Regulation | Government/Law | North America